eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Company profile
Ticker
EYEN
Exchange
Website
CEO
Sean Ianchulev
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
EYEN stock data
Latest filings (excl ownership)
8-K
Other Events
10 Apr 24
424B5
Prospectus supplement for primary offering
9 Apr 24
8-K
Entry into a Material Definitive Agreement
9 Apr 24
8-K
Other Events
8 Apr 24
8-K
Regulation FD Disclosure
19 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K/A
Regulation FD Disclosure
31 Jan 24
8-K
Regulation FD Disclosure
25 Jan 24
8-K
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine
16 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
Transcripts
EYEN
Earnings call transcript
2023 Q4
18 Mar 24
EYEN
Earnings call transcript
2023 Q3
13 Nov 23
EYEN
Earnings call transcript
2023 Q2
10 Aug 23
EYEN
Earnings call transcript
2023 Q1
11 May 23
EYEN
Earnings call transcript
2022 Q4
30 Mar 23
EYEN
Earnings call transcript
2022 Q3
11 Nov 22
EYEN
Earnings call transcript
2022 Q2
11 Aug 22
EYEN
Earnings call transcript
2022 Q1
13 May 22
EYEN
Earnings call transcript
2021 Q4
29 Mar 22
EYEN
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.70 mm | 20.70 mm | 20.70 mm | 20.70 mm | 20.70 mm | 20.70 mm |
Cash burn (monthly) | (no burn) | 380.95 k | 2.17 mm | 1.94 mm | 1.95 mm | 1.91 mm |
Cash used (since last report) | n/a | 2.55 mm | 14.53 mm | 12.99 mm | 13.02 mm | 12.77 mm |
Cash remaining | n/a | 18.15 mm | 6.17 mm | 7.71 mm | 7.68 mm | 7.93 mm |
Runway (months of cash) | n/a | 47.7 | 2.8 | 4.0 | 3.9 | 4.2 |
Institutional ownership, Q4 2023
22.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 6 |
Closed positions | 13 |
Increased positions | 10 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 16.29 bn |
Total shares | 10.67 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 4.38 mm | $9.11 bn |
Yoshida Shuhei | 1.74 mm | $8.19 mm |
Vanguard | 1.43 mm | $2.97 bn |
Ianchulev Tsontcho | 746.67 k | $2.49 mm |
Lasry Marc | 547.81 k | $1.14 bn |
STT State Street | 488.18 k | $1.02 bn |
NTRS Northern Trust | 253.25 k | $526.76 mm |
Renaissance Technologies | 243.88 k | $507.00 k |
MS Morgan Stanley | 102.39 k | $212.98 mm |
Jane Street | 91.38 k | $190.07 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Grant Stuart M. | Common stock, par value $0.0001 | Buy | Acquire P | No | No | 0.98 | 100,000 | 98.00 k | 5,430,715 |
19 Mar 24 | Grant Stuart M. | Common stock, par value $0.0001 | Buy | Acquire P | No | No | 1.23 | 50,000 | 61.50 k | 5,330,715 |
8 Mar 24 | Grant Stuart M. | Common stock, par value $0.0001 | Buy | Acquire P | No | No | 1.578 | 10,717 | 16.91 k | 5,280,715 |
4 Dec 23 | Rowe Michael M | Common Stock, par value $.0001 | Buy | Acquire P | No | No | 1.36 | 4,890 | 6.65 k | 32,927 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Apr 24
Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value
8 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Mar 24
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
19 Mar 24
Recap: Eyenovia Q4 Earnings
18 Mar 24
Press releases
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
8 Apr 24
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
18 Mar 24
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
13 Mar 24
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
4 Mar 24